VisusNano Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
VisusNano General Information
Description
Developer of a drug-eluting intraocular lens technology designed to facilitate cataract surgery. The company's lens can reduce or remove risks associated with cataract surgery, such as intraocular inflammation, infection, and opacification, enabling physicians to improve patient outcomes, obviating the need for eye drops, and avoiding the need for laser treatment after surgery.
Contact Information
Website
www.visusnano.comCorporate Office
- Lab 5 Building 500
- Discovery park, Kent
- Sandwich CT13 9ND
- England, United Kingdom
Corporate Office
- Lab 5 Building 500
- Discovery park, Kent
- Sandwich CT13 9ND
- England, United Kingdom
VisusNano Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Mar-2026 | Completed | Pre-Clinical Trials | |||
| 8. Later Stage VC | 31-May-2024 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series A) | 17-May-2022 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 02-Jun-2020 | Completed | Pre-Clinical Trials | |||
| 5. Accelerator/Incubator | 15-May-2019 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 04-Apr-2019 | Completed | Startup | |||
| 3. Accelerator/Incubator | 13-Jul-2018 | Completed | Startup | |||
| 2. Accelerator/Incubator | 22-Dec-2017 | $42.5K | Completed | Startup | ||
| 1. Accelerator/Incubator | 16-Mar-2016 | $42.5K | $42.5K | Completed | Startup |
VisusNano Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
VisusNano Patents
VisusNano Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202503488-D0 | Drug eluting devices and attachments for intraocular lenses | Inactive | 10-Mar-2025 | ||
| GB-202314432-D0 | Drug eluting devices for intraocular lenses | Inactive | 20-Sep-2023 | ||
| WO-2025062017-A1 | Drug eluting devices for intraocular lenses | Inactive | 20-Sep-2023 | ||
| EP-3777769-A1 | Drug eluting coating for medical devices | Active | 29-Feb-2016 | ||
| EP-3777769-B1 | Drug eluting coating for medical devices | Active | 29-Feb-2016 | A61L27/54 |
VisusNano Signals
VisusNano Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arrowfield Capital | Angel Group | Minority | ||
| Discovery Park Ventures | Family Office | Minority | ||
| Innvotec | Venture Capital | Minority | ||
| Innovate UK | Government | Minority | ||
| MassChallenge | Accelerator/Incubator |
VisusNano FAQs
-
When was VisusNano founded?
VisusNano was founded in 2016.
-
Where is VisusNano headquartered?
VisusNano is headquartered in Sandwich, United Kingdom.
-
What is the size of VisusNano?
VisusNano has 7 total employees.
-
What industry is VisusNano in?
VisusNano’s primary industry is Drug Delivery.
-
Is VisusNano a private or public company?
VisusNano is a Private company.
-
What is VisusNano’s current revenue?
The current revenue for VisusNano is .
-
How much funding has VisusNano raised over time?
VisusNano has raised $2.49M.
-
Who are VisusNano’s investors?
Arrowfield Capital, Discovery Park Ventures, Innvotec, Innovate UK, and MassChallenge are 5 of 8 investors who have invested in VisusNano.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process